Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02559674 · ClinicalTrials.gov registry record · Phase 1
QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel
A Phase 1 study, sponsored by Altor BioScience.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02559674 is a Phase 1 study that has completed, run by Altor BioScience. The registered enrollment target is 8 participants.
The verdict
NCT02559674, a Phase 1 study, has completed, sponsored by Altor BioScience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose escalation study of ALT-803 in combination with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer in conjunction with gemcitabine and nab-paclitaxel.
Interventions
- BIOLOGICAL Gemcitabine
- BIOLOGICAL ALT-803
- BIOLOGICAL Nab-paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-07 |
| Est. Completion | 2018-02-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02559674
The ClinicalTrials.gov registry entry for NCT02559674 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Altor BioScience, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT02559674 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02559674 about?
NCT02559674 is a clinical study titled "QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel". This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose escalation study of ALT-803 in combination with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer in conjunction with gemcitabine and nab-paclitaxel.
What is the current status of trial NCT02559674?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2016-07. Estimated completion is 2018-02-21.
What interventions are being tested in trial NCT02559674?
The interventions under investigation include: Gemcitabine (BIOLOGICAL), ALT-803 (BIOLOGICAL), Nab-paclitaxel (BIOLOGICAL).
Who is sponsoring clinical trial NCT02559674?
This trial is sponsored by Altor BioScience, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.